BACKGROUND: Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired, clonal haemopoietic stem cell disorder that causes chronic intravascular haemolysis, increases the risk of thrombosis and results in significant patient morbidity and mortality. The symptoms of PNH may have a major impact on patient quality of life. AIMS: To assess patient fatigue and health-related quality of life in 29 patients with PNH using the Functional Assessment of Chronic Illness Therapy Fatigue subscale version 4 (FACIT-Fatigue) and the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30, version 3 (EORTC QLQ-C30). METHODS: Following completion of the questionnaires, patients were interviewed to assess the validity, clarity, relevance and comprehensiveness of the assessments. RESULTS: Overall, patients considered both the FACIT-Fatigue and EORTC QLQ-C30 instruments to be relevant and adequate in assessing the level of PNH-associated fatigue and other quality-of-life measures. The FACIT-Fatigue questionnaire was considered to be clear and to comprehensively cover PNH-related fatigue. The EORTC QLQ-C30 instrument was considered to be easy to understand, but of an overall lower relevance, although some differences between countries were observed. Patients suggested additional questions that could be incorporated into future EORTC QLQ-C30 versions to make it more relevant to PNH. CONCLUSIONS: This study confirms the validity of the FACIT-Fatigue and the EORTC QLQ-C30 questionnaires in this patient population and their routine use should be considered in the management of patients with PNH.
BACKGROUND:Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired, clonal haemopoietic stem cell disorder that causes chronic intravascular haemolysis, increases the risk of thrombosis and results in significant patient morbidity and mortality. The symptoms of PNH may have a major impact on patient quality of life. AIMS: To assess patientfatigue and health-related quality of life in 29 patients with PNH using the Functional Assessment of Chronic Illness Therapy Fatigue subscale version 4 (FACIT-Fatigue) and the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30, version 3 (EORTC QLQ-C30). METHODS: Following completion of the questionnaires, patients were interviewed to assess the validity, clarity, relevance and comprehensiveness of the assessments. RESULTS: Overall, patients considered both the FACIT-Fatigue and EORTC QLQ-C30 instruments to be relevant and adequate in assessing the level of PNH-associated fatigue and other quality-of-life measures. The FACIT-Fatigue questionnaire was considered to be clear and to comprehensively cover PNH-related fatigue. The EORTC QLQ-C30 instrument was considered to be easy to understand, but of an overall lower relevance, although some differences between countries were observed. Patients suggested additional questions that could be incorporated into future EORTC QLQ-C30 versions to make it more relevant to PNH. CONCLUSIONS: This study confirms the validity of the FACIT-Fatigue and the EORTC QLQ-C30 questionnaires in this patient population and their routine use should be considered in the management of patients with PNH.
Authors: Alexander Röth; Scott T Rottinghaus; Anita Hill; Eric S Bachman; Jin Seok Kim; Hubert Schrezenmeier; Louis Terriou; Álvaro Urbano-Ispizua; Richard A Wells; Jun Ho Jang; Austin G Kulasekararaj; Jeff Szer; Rasha Aguzzi; Andrew I Damokosh; Lori Shafner; Jong Wook Lee Journal: Blood Adv Date: 2018-09-11
Authors: David Dingli; Joana E Matos; Kerri Lehrhaupt; Sangeeta Krishnan; Michael Yeh; Jesse Fishman; Sujata P Sarda; Scott B Baver Journal: Ann Hematol Date: 2022-01-01 Impact factor: 3.673
Authors: Jun Ho Jang; Jin Seok Kim; Sung-Soo Yoon; Je-Hwan Lee; Yeo-Kyeoung Kim; Deog-Yeon Jo; Jooseop Chung; Sang Kyun Sohn; Jong Wook Lee Journal: J Korean Med Sci Date: 2016-01-26 Impact factor: 2.153
Authors: Austin Kulasekararaj; Axel Glasmacher; Peng Liu; Jeff Szer; David Araten; Geraldine Rauch; Chad Gwaltney; J Rafael Sierra; Jong Wook Lee Journal: Eur J Haematol Date: 2022-03-01 Impact factor: 3.674